Ming Jiang

1.7k total citations
68 papers, 1.1k citations indexed

About

Ming Jiang is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Ming Jiang has authored 68 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pathology and Forensic Medicine and 14 papers in Molecular Biology. Recurrent topics in Ming Jiang's work include Lymphoma Diagnosis and Treatment (17 papers), Viral-associated cancers and disorders (11 papers) and CNS Lymphoma Diagnosis and Treatment (7 papers). Ming Jiang is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Viral-associated cancers and disorders (11 papers) and CNS Lymphoma Diagnosis and Treatment (7 papers). Ming Jiang collaborates with scholars based in China, United States and Hungary. Ming Jiang's co-authors include Dan Cao, Hongfeng Gou, Liqun Zou, Mei Hou, Yong‐Song Guan, Yang Yu, Yu Jiang, Yu Yang, Xi Yan and Feng Luo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Ming Jiang

57 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming Jiang China 17 404 360 239 211 186 68 1.1k
Nicola Maruotti Italy 23 378 0.9× 201 0.6× 615 2.6× 259 1.2× 162 0.9× 54 1.6k
Hirahito Endo Japan 24 218 0.5× 320 0.9× 407 1.7× 387 1.8× 144 0.8× 59 1.6k
Daniela Vivenza Italy 24 389 1.0× 270 0.8× 253 1.1× 141 0.7× 121 0.7× 57 1.4k
Μαρία Ιωάννου Greece 19 259 0.6× 113 0.3× 345 1.4× 159 0.8× 265 1.4× 91 1.2k
Yinghua Zhang China 15 700 1.7× 435 1.2× 126 0.5× 317 1.5× 56 0.3× 50 1.2k
I‐Ping Chiang Taiwan 20 213 0.5× 162 0.5× 403 1.7× 122 0.6× 129 0.7× 55 1.1k
Anne Crilly United Kingdom 17 222 0.5× 123 0.3× 395 1.7× 312 1.5× 182 1.0× 34 1.4k
Sara Szabo United States 17 327 0.8× 148 0.4× 208 0.9× 142 0.7× 81 0.4× 69 1.0k
Anna Balcerska Poland 18 271 0.7× 122 0.3× 330 1.4× 445 2.1× 57 0.3× 137 1.5k
Tian Tian China 19 279 0.7× 106 0.3× 229 1.0× 128 0.6× 97 0.5× 70 892

Countries citing papers authored by Ming Jiang

Since Specialization
Citations

This map shows the geographic impact of Ming Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Jiang more than expected).

Fields of papers citing papers by Ming Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Jiang. The network helps show where Ming Jiang may publish in the future.

Co-authorship network of co-authors of Ming Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Jiang. A scholar is included among the top collaborators of Ming Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Jiang. Ming Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Yu, et al.. (2025). Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities. Chemical Biology & Drug Design. 105(3). e70087–e70087.
2.
3.
Jiang, Ming, et al.. (2025). Unraveling the ROS-Inflammation-Immune Balance: A New Perspective on Aging and Disease. Aging and Disease. 0–0. 4 indexed citations
4.
Jiang, Ming, et al.. (2025). CRISPR/Cas12a-Based Biosensing: Advances in Mechanisms and Applications for Nucleic Acid Detection. Biosensors. 15(6). 360–360. 5 indexed citations
5.
6.
Wang, Tiansheng, Guolin Tan, Ming Jiang, et al.. (2024). SIRT5 inhibits glycolysis and nasal type extranodal NK/T cell lymphoma cell proliferation by catalyzing the desuccinylation of glucose-6-phosphate isomerase. Translational Oncology. 51. 102215–102215. 1 indexed citations
7.
Mo, Xiao‐Dong, He Huang, Feng Chen, et al.. (2024). A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment. Blood. 144(Supplement 1). 99–99. 1 indexed citations
8.
9.
Ke, Yaohua, Ying Liang, Shuxian Zhang, et al.. (2024). An Immune‐Enhancing Injectable Hydrogel Loaded with Esketamine and DDP Promotes Painless Immunochemotherapy to Inhibit Breast Cancer Growth. Advanced Healthcare Materials. 13(29). e2401373–e2401373. 6 indexed citations
10.
Jiang, Ming, et al.. (2024). Targets for improving prostate tumor response to radiotherapy. European Journal of Pharmacology. 986. 177149–177149. 3 indexed citations
11.
Wang, Shuo, Chun-Mei Deng, Yuan Zeng, et al.. (2024). Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ. 385. e078218–e078218. 26 indexed citations
12.
Jiang, Ming, Qianqian Li, Mingjie Mao, et al.. (2023). Evaluation of clinical effects of Esketamine on depression in patients with missed miscarriage: A randomized, controlled, double-blind trial. Journal of Affective Disorders. 329. 525–530. 16 indexed citations
13.
14.
15.
Zhang, Weijian, et al.. (2022). Treatment of glyphosate by-product phosphorus-containing waste salt by a combined ultrafiltration and nanofiltration process. Desalination and Water Treatment. 280. 197–205. 4 indexed citations
16.
Jiang, Ming, et al.. (2022). The value of prognostic nutritional index in nasal-type, extranodal natural killer/T-cell lymphoma. Annals of Hematology. 101(7). 1545–1556. 6 indexed citations
17.
Song, Yuqin, Keshu Zhou, Chuan Jin, et al.. (2021). A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).. Journal of Clinical Oncology. 39(15_suppl). 7529–7529. 9 indexed citations
18.
Wang, Yiqin, Li Xie, Rong Tian, et al.. (2019). PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. Journal of Cancer Research and Clinical Oncology. 145(10). 2529–2539. 12 indexed citations
19.
20.
Yan, Xi, Mei Li, Ming Jiang, et al.. (2009). Clinical characteristics of 45 patients with invasive pulmonary aspergillosis. Cancer. 115(21). 5018–5025. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicola Maruotti Breakdown of academic impact, for papers by Hirahito Endo Breakdown of academic impact, for papers by Daniela Vivenza Breakdown of academic impact, for papers by Μαρία Ιωάννου Breakdown of academic impact, for papers by Yinghua Zhang Breakdown of academic impact, for papers by I‐Ping Chiang Breakdown of academic impact, for papers by Anne Crilly Breakdown of academic impact, for papers by Sara Szabo Breakdown of academic impact, for papers by Anna Balcerska Breakdown of academic impact, for papers by Tian Tian
Rankless by CCL
2026